Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.190 -0.030 (-2.46%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Caribou Biosciences, Inc. (CRBU)

February 13, 2023

From Robbins LLP

Via Business Wire

CRBU INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CRBU

February 13, 2023

From Rosen Law Firm

Via Business Wire

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Caribou Biosciences, Inc. with Losses of $100,000 to Contact the Firm

February 13, 2023

From The Schall Law Firm

Via Business Wire

Recap: Caribou Biosciences Q2 Earnings ↗

August 09, 2022

Caribou Biosciences (NASDAQ:CRBU) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Caribou Biosciences, Inc. with Losses of $100,000 to Contact the Firm

February 11, 2023

From The Schall Law Firm

Via Business Wire

Caribou Biosciences to Participate in Upcoming Investor Conferences

February 01, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later ↗

January 25, 2023

Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.

Via InvestorPlace

Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

December 28, 2022

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

December 27, 2022

From The Schall Law Firm

Via Business Wire

Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress

December 12, 2022

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

December 12, 2022

From Caribou Biosciences, Inc.

Via GlobeNewswire

Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy ↗

December 08, 2022

-Clinical Data Due Next Week at ASH-

Via Benzinga

Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up

December 01, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug...

Via FinancialNewsMedia

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy

November 29, 2022

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

November 21, 2022

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

November 08, 2022

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

November 07, 2022

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting

November 03, 2022

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022

October 18, 2022

Ongoing complete response at 15 months reported in first patient treated with CB-010

From Caribou Biosciences, Inc.

Via GlobeNewswire

Valneva, Take-Two Interactive And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗

September 19, 2022

U.S. stock futures traded lower this morning after recording losses last week. Here are some big stocks moving lower in today’s pre-market trading session.

Via Benzinga

Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket ↗

September 19, 2022

Gainers FOXO Technologies Inc. (NYSE: FOXO) rose 161% to $10.50 in pre-market trading after dipping 52% on Friday.

Via Benzinga

Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session ↗

September 16, 2022

Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday.

Via Benzinga

Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday ↗

September 19, 2022

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

Via Benzinga

Caribou's Blood Cancer Candidate Shows Response Rates Better Than Novartis,' This Analyst Writes ↗

August 18, 2022

Via Benzinga

7 Cheap Biotech Stocks to Buy Now ↗

August 03, 2022

These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector.

Via InvestorPlace

93 Biggest Movers From Yesterday ↗

June 14, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...

Via Benzinga

Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability ↗

June 13, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 13, 2022

Via Benzinga

70 Stocks Moving In Monday's Mid-Day Session ↗

June 13, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.